Risk factors of septic shock in patients with hematologic malignancies and Pseudomonas infections

References

• Wozniak DJ, Keyser R. Effects of subinhibitory concentrations of macrolide antibiotics on pseudomonas aeruginosa. Chest 2004;124:62S–9S.
   Web of Science ®Google Scholar
• Comolli JC, Hauser AR, Waite L, Whitchurch CB, Mattick JS, Engel JN. Pseudomonas aeruginosa gene products PilT and PilU are required for cytotoxicity in vitro and virulence in a mouse model of acute pneumonia. Infect Immun 1999;67:3625–30.
   PubMed Web of Science ®Google Scholar
• Kang PJ, Hauser AR, Apodaca G, Fleiszig SM, Wiener-Kronish J, Mostov K, et al.. Identification of Pseudomonas genes required for epithelial cell injury. Mol Microbiol 1997;24:1249–62.
   PubMed Web of Science ®Google Scholar
• Mattick JS. Type IV pili and twitching motility. Annu Rev Micrbiol 2002;56:289–314.
   PubMed Web of Science ®Google Scholar
• Pollack M. Pseudomonas aeruginosa. In: , Mandell G L, Bennett J E, Dolin R, eds. Mandell, Douglas and Bennett’s principles and practice of infectious diseases, 5th ed, Vol. 2. Philadelphia, PA: Chircill Livingstone; 2000. p. 2310–9.
   Google Scholar
• Bisbe J, Gatell JM, Puig J, Mallolas J, Martinez JA, Jimenez de Anta MT, et al.. Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factors influencing the prognosis in 133 episodes. Rev Infect Dis 1998;10:629–35.
   Google Scholar
• Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patient with cancer. Retrospective analysis of 245 episodes. Arch Intern Med 2000;160:501–9.
   PubMed Web of Science ®Google Scholar
• Gallagher PG, Watenakunakorn C. Pseudomonas bacteremia in a community teaching hospital, 1980–1984. Rev Infect Dis 1989;11:846–52.
   PubMedGoogle Scholar
• Vidal F, Mensa J, Almela M, Martínez JA, Marco F, Casals C, et al.. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 1996;156:2121–6.
   PubMed Web of Science ®Google Scholar
• Kuikha A, Valtonen VV. Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish University Hospital. Eur J Clin Microbiol Infect Dis 1998;17:701–8.
   PubMed Web of Science ®Google Scholar
• Hughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, Meyers JD, et al.. From the infectious diseases society of America. Guidelines for the use of the antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:381–96.
   PubMed Web of Science ®Google Scholar
• Scimpff SC, Greene WH, Young VM, Wiernick PH. Significance of Pseudomonas aeruginosa in the patient with leukemia and lymphoma. J Infect Dis 1974;130(Suppl):S24–31.
   PubMedGoogle Scholar
• Tapper ML, Armstrong D. Bacteremia due to Pseudomonas aeruginosa complicating neoplastic disease: a progress report. J Infect Dis 1974;130(Suppl):S14–23.
   PubMedGoogle Scholar
• Osmon S, Ward S, Frakr VJ, Kollef MH. Hospital mortality for patients with bacteremia due to staphylococcus aureus or Pseudomonas aeruginosa. Chest 2004;125:607–16.
   PubMed Web of Science ®Google Scholar
• Kollef MH. Inadequate antimicrobial treatment: an important determinant of hospitalized patients. Clin Infect Dis 2000;31:S131–8.
   PubMed Web of Science ®Google Scholar
• Kollef MH, Sherman G, Ward S, Fraser FJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462–74.
   PubMed Web of Science ®Google Scholar
• Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcome in the ICU setting. Chest 2000;118:146–55.
   PubMed Web of Science ®Google Scholar
• Carnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar AE, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003;31:2742–51.
   PubMed Web of Science ®Google Scholar
• Ohmagari N, Hanna H, Graviss L, Hackett B, Perego C, Gonzalez V. Risk factors for infection with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer 2005;104:205–12.
   PubMed Web of Science ®Google Scholar
• Carmeli Y, Troiller N, Karchmer AW, Somoh MH. Health and economic outcomes of antibiotic resistance in pseudomonas aeruginosa. Arch Intern Med 1999;159:1127–32.
   PubMed Web of Science ®Google Scholar
• Hachem RY, Chemaly RF, Ahmar CA, Jiang Y, Boktour MR, Rjaili GA. Colistin is effective in treatment of infections caused by Multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother 2007;51:1905–11.
   PubMed Web of Science ®Google Scholar
• Hammoud SP, Baden LR. Antibiotic prophylaxis during chemotherapy-induced neutropenia for patients with acute leukemia. Curr Hematol Malig Rep 2007;2:97–103.
   PubMedGoogle Scholar
• Sevransky J. Clinical assessment of hemodynamically unstable patients. Curr Opin Crit Care 2009;15:234–8.
   PubMed Web of Science ®Google Scholar
• Arkader R, Troster EJ, Lopes MR, Júnior RR, Carcillo JA, Leone C, et al.. Procalcitonin does discriminate between sepsis and systemic inflammatory response syndrome. Arch Dis Child 2006;91:117–20.
   PubMed Web of Science ®Google Scholar
• James JH, Luchette FA, McCarter FD, Fischer JE. Lactate is an unreliable indicator of tissue hypoxia in injury or sepsis. Lancet 1999;354:505–8.
   PubMed Web of Science ®Google Scholar
• Nguyen HB, Rivers EP, Knoblich BP, Jacobsen G, Muzzin A, Ressler JA, et al.. Early lactate clearance is associated with improved outcome in severe sepsis and septic shock. Crit Care Med 2004;32:1637–42.
   PubMed Web of Science ®Google Scholar
• Rivers EP, McIntyre L, Morro DC, Rivers KK. Early and innovative interventions for severe sepsis and septic shock: taking advantage of a window of opportunity. CMAJ 2005;173:1054–65.
   PubMed Web of Science ®Google Scholar
• Spronk PE, Zandestra DF, Ince C. Bench-to-bedside review: sepsis is a disease of the microcirculation. Crit Care 2004;8:462–8.
   PubMed Web of Science ®Google Scholar
• Aduen J, Bernstein WK, Khastgir T, Miller J, Kerzner R, Bhatiani A, et al.. The use and clinical importance of a substrate-specific electrode for rapid determination of blood lactate concentrations. JAMA 1994;272:1678–85.
   PubMed Web of Science ®Google Scholar
• Aird WC. The hematologic system as a marker of organ dysfunction in sepsis. Mayo Clin Proc 2003;78:869–81.
   PubMed Web of Science ®Google Scholar
• Jeddi R, Achour M, Ben Amor R, Aissaoui L, Bouterâa W, Kacem K, et al.. Factors associated with severe sepsis: prospective study of 94 neutrpenic febrile episodes. Hematology 2010;15:28–32.
   PubMed Web of Science ®Google Scholar
• Brunelli SM, Goldfarb S. Hypophosphatemia: clinical consequences and management. J Am Soc Nephrol 2007;18:1999–2003.
   PubMed Web of Science ®Google Scholar
• Wilkes P. Hypoproteinemia, strong ion difference, and acid-base status in critically ill patients. J Appl Physiol 1998;84:1740–8.
   PubMed Web of Science ®Google Scholar
• Margrson MP, Soni NC. Effects of albumin supplementation on microvascular permeability in septic patients. J Appl Physiol 2001;92:2139–45.
   Web of Science ®Google Scholar
• Osih RB, McGregor JC, Rich SE, Moore AC, Furuno JP, Perencevich EN, et al.. Impact of empiric antibiotic therapy on outcome in patients with pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2007;51:839–44.
   PubMed Web of Science ®Google Scholar
• Siegman-Igra Y, Ravona R, Primerman H, Giladi M. Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy. Int J Infect Dis 1998;2:211–5.
   PubMedGoogle Scholar
• Aliago L, Mediavilla JD, Cobo F. A clinical index predicting mortality with Pseudomonas aeruginosa bacteraemia. J Med Microbiol 2002;51:615–9.
   PubMed Web of Science ®Google Scholar
• Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia: retrospective analysis of 410 episodes. Arch Intern Med 1985;145:1621–9.
   PubMed Web of Science ®Google Scholar
• Bryan CS, Reynolds KL, Brenner ER. Analysis of 1,186 episodes of Gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy. Rev Infect Dis 1983;5:629–38.
   PubMedGoogle Scholar
• Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al.. Bloodstream infections caused by antibiotic resistant Gram-negative bacilli: risk factors for mortality and influence delayed receipt of antimicrobial therapy on clinical outcome. Clin Infect Dis 2003;37:745–51.
   PubMed Web of Science ®Google Scholar
• Harris A, Torres-Viera C, Venkataraman L, DeGirolami P, Samore M, Carmeli Y, et al.. Epidemiology and clinical outcome of patients with multiresistant pseudomonas aeruginosa. Clin Infect Dis 1999;28:1128–33.
   PubMed Web of Science ®Google Scholar